Supply of Medicine and Medical / Surgical equipments : Anti-A Blood grouping Reagent- Monoclonal-\nDirect Agglutining 10ml\n1. The method of manufacture should result\nin a product within an immediate container\nthat is homogeneous and free of properties\nwhich adversely affect its intended use\nthroughout its recommended shelf life. The\nreagent should have no precipitate, particles\nor fibrin gel.\n2. Each batch or sub-batch should be\nspecifically identified by a distinctive\ncombination of numbers and/or letters (batch\nreference) which permits its history to be\ntraced.\n3. Reagents should be produced by a\nvalidated process that is shown to be suitable\nfor the intended purpose.\n4. Volume should be mentioned in milliliters\n(ml) on immediate container\n5. Absence of rouleaux formation, prozone\nand haemolysis.\n6. Labelling requirements; A. Should have a\nlabel on the immediate container B. Printing\non all final container labels shall be in solid\nblack. C. The label fixed to the immediate\ncontainer of a reagent should leave\nuncovered sufficient area of the full length or\ncircumference of the container to allow ready\nvisual inspection of the contents. D. The\nspecificity of the reagent for blood group\nserology should be of a print size which is\nclearly legible. The print size of other\ninformation on the label should not exceed\nthat used for the specificity of the reagent.\nE. Should include Lot number and sub lot\ndesignations, if available F. Expiry date\nshould be mentioned. G. Should mention the\nrecommended storage temperature (2-6 C)\n7. Precautions must be taken to maintain the\ncold chain while transportation until it reaches\nthe blood bank, as these reagents are kept at etc .

STATE PHARMACEUTICALS CORPORATION OF SRI LANKA Sri Lanka has Released a tender for Supply of Medicine and Medical / Surgical equipments : Anti-A Blood grouping Reagent- Monoclonal-\nDirect Agglutining 10ml\n1. The method of manufacture should result\nin a product within an immediate container\nthat is homogeneous and free of properties\nwhich adversely affect its intended use\nthroughout its recommended shelf life. The\nreagent should have no precipitate, particles\nor fibrin gel.\n2. Each batch or sub-batch should be\nspecifically identified by a distinctive\ncombination of numbers and/or letters (batch\nreference) which permits its history to be\ntraced.\n3. Reagents should be produced by a\nvalidated process that is shown to be suitable\nfor the intended purpose.\n4. Volume should be mentioned in milliliters\n(ml) on immediate container\n5. Absence of rouleaux formation, prozone\nand haemolysis.\n6. Labelling requirements; A. Should have a\nlabel on the immediate container B. Printing\non all final container labels shall be in solid\nblack. C. The label fixed to the immediate\ncontainer of a reagent should leave\nuncovered sufficient area of the full length or\ncircumference of the container to allow ready\nvisual inspection of the contents. D. The\nspecificity of the reagent for blood group\nserology should be of a print size which is\nclearly legible. The print size of other\ninformation on the label should not exceed\nthat used for the specificity of the reagent.\nE. Should include Lot number and sub lot\ndesignations, if available F. Expiry date\nshould be mentioned. G. Should mention the\nrecommended storage temperature (2-6 C)\n7. Precautions must be taken to maintain the\ncold chain while transportation until it reaches\nthe blood bank, as these reagents are kept at etc . in Pharmaceuticals. The tender was released on Feb 14, 2025.

Country - Sri Lanka

Summary - Supply of Medicine and Medical / Surgical equipments : Anti-A Blood grouping Reagent- Monoclonal-\nDirect Agglutining 10ml\n1. The method of manufacture should result\nin a product within an immediate container\nthat is homogeneous and free of properties\nwhich adversely affect its intended use\nthroughout its recommended shelf life. The\nreagent should have no precipitate, particles\nor fibrin gel.\n2. Each batch or sub-batch should be\nspecifically identified by a distinctive\ncombination of numbers and/or letters (batch\nreference) which permits its history to be\ntraced.\n3. Reagents should be produced by a\nvalidated process that is shown to be suitable\nfor the intended purpose.\n4. Volume should be mentioned in milliliters\n(ml) on immediate container\n5. Absence of rouleaux formation, prozone\nand haemolysis.\n6. Labelling requirements; A. Should have a\nlabel on the immediate container B. Printing\non all final container labels shall be in solid\nblack. C. The label fixed to the immediate\ncontainer of a reagent should leave\nuncovered sufficient area of the full length or\ncircumference of the container to allow ready\nvisual inspection of the contents. D. The\nspecificity of the reagent for blood group\nserology should be of a print size which is\nclearly legible. The print size of other\ninformation on the label should not exceed\nthat used for the specificity of the reagent.\nE. Should include Lot number and sub lot\ndesignations, if available F. Expiry date\nshould be mentioned. G. Should mention the\nrecommended storage temperature (2-6 C)\n7. Precautions must be taken to maintain the\ncold chain while transportation until it reaches\nthe blood bank, as these reagents are kept at etc .

Deadline - Mar 24, 2025

MT reference number - 103330963

Product classification - Pharmaceutical products